Commonwealth Financial Services’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Commonwealth Financial Services’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	$947K	Buy	23,046 +1,827	+9%	+$76.6K	1.03%	8
2016 Q4	$843K	Hold	21,219	–	–	0.83%	16
2016 Q3	$890K	Hold	21,219	–	–	0.84%	18
2016 Q2	$785K	Hold	21,219	–	–	0.92%	15
2016 Q1	$812K	Hold	21,219	–	–	1.2%	7
2015 Q4	$1.07M	Buy	21,219 +11,995	+130%	+$593K	3.64%	7
2015 Q3	$422K	Hold	9,224	–	–	0.49%	20
2015 Q2	$538K	Hold	9,224	–	–	0.58%	13
2015 Q1	$509K	Hold	9,224	–	–	0.45%	16
2014 Q4	$463K	Buy	+9,224	New	+$451K	0.41%	27

Other funds holding PBE

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SAM

SignalPoint Asset Management Springfield, Missouri $411M AUM 23.81% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Commonwealth Financial Services's PBE Position: Q1 2017 in Review

Commonwealth Financial Services increased its Invesco Biotechnology & Genome ETF (PBE) stake by 8.6% in Q1 2017, buying an estimated $76.6K and bringing the position to 23,046 shares worth $947K. The position accounts for 1.03% of the portfolio, ranked #8.

Commonwealth Financial Services first reported a position in PBE in Q4 2014 and has held it in 10 quarters since. The position peaked at $1.07M in Q4 2015. 68 funds tracked by Wall St. Rank hold PBE as of Q1 2017.

Commonwealth Financial Services held 23,046 shares of Invesco Biotechnology & Genome ETF worth $947K as of Q1 2017.
Commonwealth Financial Services bought 1,827 Invesco Biotechnology & Genome ETF shares in Q1 2017, an estimated $76.6K.
Invesco Biotechnology & Genome ETF made up 1.03% of Commonwealth Financial Services's portfolio in Q1 2017, its #8 holding.
Commonwealth Financial Services first reported a position in Invesco Biotechnology & Genome ETF in Q4 2014 and has held it in 10 quarters since.
Commonwealth Financial Services's Invesco Biotechnology & Genome ETF position peaked at $1.07M in Q4 2015.
68 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q1 2017.

Based on Commonwealth Financial Services's 13F filing for Q1 2017, filed 20 Apr 2017.